NCT06917313 - FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

DRUG

Fezolinetant

45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks

DRUG

Placebo

45 mg tablets, administered orally once daily with or without food, to be taken throughout the entire study phase, i.e. 12 weeks

Trial Locations (1)

Yale University, New Haven

All Listed Sponsors

collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Yale University

OTHER